PRISM Oncology Series · RWID Multimodal
Prostate Cancer & PSMA Insights
Longitudinal prostate cancer cohort integrating multimodal clinical, imaging, laboratory, and pathology data across the disease continuum, with PSMA PET as a core element throughout staging, biochemical recurrence, oligometastatic evaluation, and Lu-177 radioligand therapy assessment.
PSMA PET/CT showing radiotracer uptake in prostate cancer. Imaging aligned to clinical scenario classification across the disease continuum. De-identified.
8,039
Patients in cohort
2021–26
Time frame coverage
5
Clinical scenarios classified
Quarterly
Data refresh cycle
Dataset Specifications
What is in the PRISM Prostate Cancer & PSMA Insights Dataset
Structured EHR elements linked to imaging, laboratory, and pathology data, with temporal alignment to PSMA PET index events across the disease continuum.
Therapeutic Area
Oncology
Disease Focus
Prostate cancer · all stages · including castration-sensitive and castration-resistant disease
Treatment Types
Surgery, radiotherapy, androgen deprivation therapy (ADT) · androgen receptor pathway inhibitors · chemotherapy · radioligand therapy (Pluvicto / Lu-177 vipivotide tetraxetan)
Imaging Modalities
PSMA PET (⁶⁸Ga-PSMA-11, ¹⁸F-DCFPyL) · prostate MRI · conventional imaging
Clinical Data (EHR)
Demographics · diagnoses · procedures (CPT-coded) · medications · pharmacy dispensing · pathology (Gleason score) · labs (PSA, testosterone, hematologic and biochemical markers)
Data Sources
Oncology · urology · pharmacy dispensing · radiology (DICOM) · nuclear medicine (DICOM) · pathology · laboratory
Data Format & Compliance
Raw DICOMs and structured clinical data · HIPAA de-identified · Provenance documentation built into acquisition · Longitudinal timeline reconstruction with temporal alignment to PSMA PET index events
Clinical Scenarios
Five clinical scenarios classified across the disease continuum
Each PSMA PET event is classified into a clinical scenario using rule-based algorithms incorporating temporal relationships, PSA dynamics, prior treatments, and castration status.
Primary staging
Initial diagnosis: PSMA PET for staging at first presentation, aligned to biopsy, Gleason score, and baseline PSA.
Biochemical recurrence
Post-definitive therapy: PSMA PET triggered by PSA rise following prior surgery or radiation, with linked treatment history and time-to-recurrence data.
Oligometastatic disease evaluation
Limited Metastatic Burden: PSMA PET for characterization of oligometastatic disease, with linked imaging and treatment decision data.
Castration-resistant disease
Advanced progression: PSMA PET in the context of CRPC, aligned to treatment sequences and PSA kinetics.
PSMA-targeted therapy (Pluvicto)
Theranostics: PSMA PET for therapy selection and monitoring related to Lu-177 vipivotide tetraxetan (Pluvicto), with linked dosimetry, response, and outcomes data.
Applications
What this dataset enables
From theranostics research to predictive modelling across the prostate cancer continuum.
Theranostics & radioligand therapy research
Characterize patient selection, response, and outcomes for Lu-177 Pluvicto therapy using linked PSMA PET imaging, PSA dynamics, and treatment data across real-world populations.
Imaging biomarker development
Build and validate PSMA-derived imaging biomarkers, including SUV metrics, tumor volume, and lesion detection, using longitudinal imaging linked to clinical outcomes.
Disease progression modelling
Model transitions across clinical scenarios (primary → recurrence → CRPC → RLT) using temporally aligned imaging, labs, and treatment sequences.
Predictive & response models
Model transitions across clinical scenarios (primary → recurrence → CRPC → RLT) using temporally aligned imaging, labs, and treatment sequences.
Clinical trial feasibility
Model eligibility criteria, patient volumes, and endpoint distributions for prostate cancer trials using real-world data across 8,000+ patients with PSMA PET.
Comparative effectiveness & real-world evidence
Compare outcomes across treatment sequences (ADT, AR inhibitors, chemotherapy, RLT) in the real-world population, supporting label expansion and post-marketing evidence generation.
Biomarkers & Endpoints
Key biomarkers and endpoints available for selection
Imaging, laboratory, and pathology biomarkers with longitudinal temporal alignment. Biomarker selection is tailored to your programme's endpoints and therapeutic objectives.
PSMA PET Imaging
- PSMA PET uptake (SUV metrics)
- Lesion count and distribution
- Total tumor volume (PSMA-positive)
- Lesion-level anatomic classification
- Response assessment (pre/post therapy)
Laboratory
- Prostate-specific antigen (PSA)
- PSA kinetics (doubling time, velocity)
- Testosterone levels
- Hematologic markers
- Biochemical markers
Pathology
- Gleason score
- Grade group classification
- Histologic subtype
Clinical & Treatment
- Treatment sequencing and timing
- Castration status
- Time to biochemical recurrence
- Time to castration resistance
- Overall survival indicators
Dataset Request
Request access to PRISM Series RWID Multimodal Cohorts
Receive technical specifications for the pre-built research cohort relevant to your programme.
